ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5159.41M
Enterprise Value 3101.58M
Trailing P/E N/A
Forward P/E 1-2.31
PEG Ratio (5 yr expected) 1-0.05
Price/Sales (ttm)3.69
Price/Book (mrq)2.54
Enterprise Value/Revenue 32.35
Enterprise Value/EBITDA 6-0.93

Trading Information

Stock Price History

Beta (3Y Monthly) 2.25
52-Week Change 3-76.75%
S&P500 52-Week Change 37.40%
52 Week High 329.49
52 Week Low 34.20
50-Day Moving Average 35.17
200-Day Moving Average 37.52

Share Statistics

Avg Vol (3 month) 3399.07k
Avg Vol (10 day) 3390.84k
Shares Outstanding 527.53M
Float 15.61M
% Held by Insiders 12.11%
% Held by Institutions 1114.84%
Shares Short (Jun 14, 2019) 45.23M
Short Ratio (Jun 14, 2019) 412.25
Short % of Float (Jun 14, 2019) 429.59%
Short % of Shares Outstanding (Jun 14, 2019) 418.99%
Shares Short (prior month May 15, 2019) 45.75M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -291.22%
Operating Margin (ttm)-256.38%

Management Effectiveness

Return on Assets (ttm)-26.52%
Return on Equity (ttm)-107.64%

Income Statement

Revenue (ttm)43.16M
Revenue Per Share (ttm)1.58
Quarterly Revenue Growth (yoy)356.90%
Gross Profit (ttm)33.41M
EBITDA -109.2M
Net Income Avi to Common (ttm)-125.69M
Diluted EPS (ttm)-4.61
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)190.64M
Total Cash Per Share (mrq)6.92
Total Debt (mrq)130.59M
Total Debt/Equity (mrq)204.32
Current Ratio (mrq)7.03
Book Value Per Share (mrq)2.32

Cash Flow Statement

Operating Cash Flow (ttm)-100.34M
Levered Free Cash Flow (ttm)-69.36M